EGFR and pancreatic neoplasm: For instance, EGFR-CD3 BiTE 34-36 armed activated T cells could enhance subsequent responsiveness to chemotherapeutic drugs, but the impact of the BiTE in pancreatic tumor microenvironment on the activity and infiltration of T cells remains to be fully understood.